FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360600195> ?p ?o ?g. }

• W4360600195 endingPage "1845" @default.
• W4360600195 startingPage "1836" @default.
• W4360600195 abstract "Abstract Background The optimal treatment strategy for patients with small human epidermal growth factor receptor 2 (HER2)‐positive tumors is based on nodal status. The authors’ objective was to evaluate pathologic nodal disease (pathologic lymph node‐positive [pN‐positive] and pathologic lymph node‐positive after preoperative systemic therapy [ypN‐positive]) rates in patients who had clinical T1–T2 (cT1–cT2)N0M0, HER2‐positive breast cancer treated with upfront surgery or neoadjuvant chemotherapy (NAC). Methods Two databases were queried for patients who had cT1–cT2N0M0, HER2‐positive breast cancer: (1) the Dana‐Farber Brigham Cancer Center (DF/BCC) from February 2015 to October 2020 and (2) the Hospital Clinic of Barcelona and the Hospital Clinico of Valencia (HCB/HCV) from January 2012 to September 2021. The pN‐positive/ypN‐positive and axillary lymph node dissection (ALND) rates were compared between patients who underwent upfront surgery versus those who received NAC. Results Among 579 patients from the DF/BCC database, 368 underwent upfront surgery, and 211 received NAC; the rates of nodal positivity were 19.8% and 12.8%, respectively ( p = .021). The pN‐positive rates increased by tumor size ( p < .001), reaching 25% for those with cT1c tumors. The ypN‐positive rates did not correlate with tumor size. NAC was associated with decreased nodal positivity (odds ratio, 0.411; 95% confidence interval, 0.202–0.838), but the ALND rates were similar (22 of 368 patients [6.0%] who underwent upfront surgery vs. 18 of 211 patients [8.5%] who received NAC; p = .173). Among 292 patients from the HCB/HCV database, 119 underwent upfront surgery, and 173 received NAC; the rates of nodal positivity were 21% and 10.4%, respectively ( p = .012). The pN‐positive rates increased with tumor size ( p = .011). The ALND rates were equivalent by treatment strategy (23 of 119 patients [19.3%] who underwent upfront surgery vs. 24 of 173 patients [13.9%] who received NAC; p = .213). Conclusions Among patients who had cT1–cT2N0M0, HER2‐positive breast cancer, approximately 20% who underwent upfront surgery were pN‐positive, and the rate reached 25% for those with cT1c tumors. Given the opportunity for tailored therapy among lymph node‐positive, HER2‐positive patients, these data provide rationale for future analyses investigating the utility of routine axillary imaging in patients with HER2‐positive breast cancer." @default.
• W4360600195 created "2023-03-24" @default.
• W4360600195 creator A5012303632 @default.
• W4360600195 creator A5013081121 @default.
• W4360600195 creator A5014201549 @default.
• W4360600195 creator A5015289835 @default.
• W4360600195 creator A5020313654 @default.
• W4360600195 creator A5029062544 @default.
• W4360600195 creator A5039153082 @default.
• W4360600195 creator A5039694693 @default.
• W4360600195 creator A5041405457 @default.
• W4360600195 creator A5065532212 @default.
• W4360600195 creator A5069056507 @default.
• W4360600195 creator A5070245248 @default.
• W4360600195 creator A5076310424 @default.
• W4360600195 creator A5081854007 @default.
• W4360600195 creator A5089513581 @default.
• W4360600195 creator A5089866079 @default.
• W4360600195 date "2023-03-23" @default.
• W4360600195 modified "2023-10-06" @default.
• W4360600195 title "Nodal positivity and systemic therapy among patients with clinical T1–T2N0 human epidermal growth factor receptor‐positive breast cancer: Results from two international cohorts" @default.
• W4360600195 cites W1984107586 @default.
• W4360600195 cites W2070281077 @default.
• W4360600195 cites W2095633632 @default.
• W4360600195 cites W2101979288 @default.
• W4360600195 cites W2129395303 @default.
• W4360600195 cites W2137853125 @default.
• W4360600195 cites W2139510434 @default.
• W4360600195 cites W2516525501 @default.
• W4360600195 cites W2795193052 @default.
• W4360600195 cites W2806209829 @default.
• W4360600195 cites W2902218997 @default.
• W4360600195 cites W2928807055 @default.
• W4360600195 cites W3162334759 @default.
• W4360600195 cites W3165177412 @default.
• W4360600195 cites W3179495039 @default.
• W4360600195 cites W4214660429 @default.
• W4360600195 doi "https://doi.org/10.1002/cncr.34750" @default.
• W4360600195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36951169" @default.
• W4360600195 hasPublicationYear "2023" @default.
• W4360600195 type Work @default.
• W4360600195 citedByCount "1" @default.
• W4360600195 countsByYear W43606001952023 @default.
• W4360600195 crossrefType "journal-article" @default.
• W4360600195 hasAuthorship W4360600195A5012303632 @default.
• W4360600195 hasAuthorship W4360600195A5013081121 @default.
• W4360600195 hasAuthorship W4360600195A5014201549 @default.
• W4360600195 hasAuthorship W4360600195A5015289835 @default.
• W4360600195 hasAuthorship W4360600195A5020313654 @default.
• W4360600195 hasAuthorship W4360600195A5029062544 @default.
• W4360600195 hasAuthorship W4360600195A5039153082 @default.
• W4360600195 hasAuthorship W4360600195A5039694693 @default.
• W4360600195 hasAuthorship W4360600195A5041405457 @default.
• W4360600195 hasAuthorship W4360600195A5065532212 @default.
• W4360600195 hasAuthorship W4360600195A5069056507 @default.
• W4360600195 hasAuthorship W4360600195A5070245248 @default.
• W4360600195 hasAuthorship W4360600195A5076310424 @default.
• W4360600195 hasAuthorship W4360600195A5081854007 @default.
• W4360600195 hasAuthorship W4360600195A5089513581 @default.
• W4360600195 hasAuthorship W4360600195A5089866079 @default.
• W4360600195 hasConcept C121608353 @default.
• W4360600195 hasConcept C126322002 @default.
• W4360600195 hasConcept C143998085 @default.
• W4360600195 hasConcept C156957248 @default.
• W4360600195 hasConcept C2780212769 @default.
• W4360600195 hasConcept C2780849966 @default.
• W4360600195 hasConcept C2908728163 @default.
• W4360600195 hasConcept C2908949552 @default.
• W4360600195 hasConcept C44249647 @default.
• W4360600195 hasConcept C530470458 @default.
• W4360600195 hasConcept C71924100 @default.
• W4360600195 hasConcept C83330619 @default.
• W4360600195 hasConceptScore W4360600195C121608353 @default.
• W4360600195 hasConceptScore W4360600195C126322002 @default.
• W4360600195 hasConceptScore W4360600195C143998085 @default.
• W4360600195 hasConceptScore W4360600195C156957248 @default.
• W4360600195 hasConceptScore W4360600195C2780212769 @default.
• W4360600195 hasConceptScore W4360600195C2780849966 @default.
• W4360600195 hasConceptScore W4360600195C2908728163 @default.
• W4360600195 hasConceptScore W4360600195C2908949552 @default.
• W4360600195 hasConceptScore W4360600195C44249647 @default.
• W4360600195 hasConceptScore W4360600195C530470458 @default.
• W4360600195 hasConceptScore W4360600195C71924100 @default.
• W4360600195 hasConceptScore W4360600195C83330619 @default.
• W4360600195 hasFunder F4320325516 @default.
• W4360600195 hasIssue "12" @default.
• W4360600195 hasLocation W43606001951 @default.
• W4360600195 hasLocation W43606001952 @default.
• W4360600195 hasOpenAccess W4360600195 @default.
• W4360600195 hasPrimaryLocation W43606001951 @default.
• W4360600195 hasRelatedWork W111573635 @default.
• W4360600195 hasRelatedWork W1970285512 @default.
• W4360600195 hasRelatedWork W1973855633 @default.
• W4360600195 hasRelatedWork W1996753309 @default.
• W4360600195 hasRelatedWork W2032808049 @default.
• W4360600195 hasRelatedWork W2161568138 @default.
• W4360600195 hasRelatedWork W2224319365 @default.
• W4360600195 hasRelatedWork W2317313649 @default.

• next